Sanofi US
NEWS
Sanofi, Certara, Pfizer and Thermo Fisher are facing hiring challenges head-on with a common strategy: upskilling programs. They use these programs to fill open roles while training and retaining existing talent.
Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.
Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.
Boehringer, Evotec and bioMérieux found Aurobac to combat antimicrobial resistance, Turnstone and Moffitt Expand TIL Collab, Skyhawk to gain potential $2B from Sanofi RNA splicing deal.
It’s been a busy month for big biopharma companies looking to expand operations with Moderna, AstraZeneca, Sanofi and more are setting up new facilities internationally.
The new space will enable Astellas to establish a global supply chain of gene therapies as well as widen the scope of the therapeutic products it creates.
The approval expands the rapidly growing number of indications for Dupixent, which is the first and only biologic medication with the FDA’s nod to treat atopic dermatitis from infancy to adulthood.
Sanofi will study its SAR444245 in combination with Immunocore’s KIMMTRAK in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers.
Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
JOBS
IN THE PRESS